ArticleBMC medical imaging2026
A multicenter study on preoperative WHO/ISUP grading of clear cell renal cell carcinoma using triphasic contrast-enhanced CT-based habitat imaging.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to develop a triphasic contrast-enhanced CT-based habitat imaging method for preoperative prediction of World Health Organization/International Society of Urological Pathology (WHO/ISUP) grade in clear cell renal cell carcinoma (ccRCC).
methodsA retrospective analysis included 300 ccRCC patients from two centers. Center 1 data were used for training (n = 190) and internal validation (n = 82), and Center 2 for external validation (n = 28). All patients underwent triphasic CT scans. Tumor volumes of interest (VOIs) were manually delineated using 3D Slicer. CT values from the corticomedullary (CMP), nephrographic (NP), and excretory (EP) phases were extracted to assess enhancement. K-means clustering segmented tumors into four habitats, and volume fractions were calculated. Logistic regression identified significant predictors from habitat features and clinical variables. A nomogram was constructed and evaluated using receiver operating characteristic (ROC) curves, area under the curve (AUC), calibration curves, Hosmer-Lemeshow (HL) tests, and decision curve analysis (DCA).
resultsGender, tumor size, and the volume fractions of Habitat 1 (F1) and Habitat 2 (F2) were independent predictors. These predictors were integrated into a nomogram that achieved AUCs of 0.794 (95% CI, 0.726–0.862) in the training cohort, 0.787 (95% CI, 0.678–0.897) in the internal validation cohort, and 0.781 (95% CI, 0.599–0.962) in the external validation cohort. The model showed acceptable calibration and yielded potential net clinical benefit in both validation sets.
conclusionWe developed and externally validated a CT-based nomogram for preoperative WHO/ISUP grade stratification in ccRCC; larger independent cohorts are needed to confirm generalizability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.